论文部分内容阅读
目的:对新型口服抗糖尿病药物瑞格列奈(Repagllnldc,诺和龙)的疗效进行评价。方法:2型糖尿病患者34例,瑞格列奈治疗前一月内测定对照空腹血糖、餐后2小时血糖、糖化血红蛋白(HbA_1c)、血脂、体重、身高,观察过程中,饮食及运动量同前不变,经其它降糖药物治疗血糖3个月控制不佳者,改服或加服瑞格列奈0.5mg,2次/日,如2周后餐后2小时血糖≥11.1mmol/L,则加至0.5mg.3次/日,疗程8周,治疗8周后复查空腹血糖、餐后2小时血糖、HbA_1C、血脂、体重。结果:与治疗前比较,空腹血糖、餐后2小时血糖、HbA_1C均有显著下降,空腹血糖下降0.9mmol/L(P<0.05),餐后2小时血糖下降5.68mmol/L(P<0.05),HbA_2C下降1.54%(P<0.05);而体重指数、血脂治疗前后无显著性差异。瑞格列奈治疗中出现较轻的腹胀、头痛、低血糖等副作用,其中低血糖发生率12%。结论:在为期8周的治疗中,瑞格列奈对2型糖尿病患者的空腹血糖、餐后2小时血糖、HbA_1C均有明显下降,能模拟生理性胰岛素分泌,起到“餐时血糖调节剂”作用,发生低血糖频率低,副作用轻微,患者顺应性、安全性较好。
Objective: To evaluate the efficacy of a new oral antidiabetic drug repaglinide (Novozymes). Methods: 34 cases of type 2 diabetes mellitus, fasting blood glucose, 2 hours postprandial blood glucose, glycosylated hemoglobin (HbA_1c), blood fat, body weight and height were measured in the first month before repaglinide treatment. Unchanged, other hypoglycemic drugs for treatment of blood sugar 3 months poor control, change clothes or add repaglinide 0.5mg, 2 times / day, such as 2 weeks after 2 hours of postprandial blood glucose ≥ 11.1mmol / L, Then added to 0.5mg.3 times / day, the course of treatment for 8 weeks, 8 weeks after treatment, fasting blood glucose, 2 hours postprandial blood glucose, HbA_1C, lipids, body weight. Results: Fasting plasma glucose, HbA1C, fasting blood glucose (HbA_1C) decreased significantly (P <0.05) and fasting blood glucose decreased by 5.6mmol / L (P <0.05) , HbA_2C decreased by 1.54% (P <0.05), while body mass index and blood lipid had no significant difference before and after treatment. Repaglinide treatment appeared lighter abdominal distension, headache, hypoglycemia and other side effects, including the incidence of hypoglycemia 12%. CONCLUSIONS: During the 8-week treatment, repaglinide has markedly decreased fasting blood glucose, 2-hour postprandial blood glucose and HbA 1 C in type 2 diabetic patients, which can simulate physiological insulin secretion and play a role of “mealtime blood glucose regulators ”The role of hypoglycemia occurred with low side effects, patient compliance, better safety.